Sunshine Lake Pharma (SEHK:6887) After Deepening Half Year Losses Looks Caught Between Value Signals

Sunshine Lake Pharma (SEHK:6887) just released half year results to June 30, 2026, reporting sales of CNY 1,075.31 million and a net loss of CNY 603.72 million, which sharply widened compared with last year.

At a share price of HK$36.96, Sunshine Lake Pharma has seen short term share price momentum cool, with the 7 day share price return down 1.39% and year to date share price return down 17.20%. However, the 3 year total shareholder return of 59.16% and 5 year total shareholder return of 133.39% still indicate a much stronger longer term outcome for investors who remained invested over multiple years.

Scan beyond Sunshine Lake Pharma and see how other high quality stocks with strong fundamentals and resilient balance sheets are trading with our curated list of solid balance sheet and fundamentals (194 results)

Sunshine Lake Pharma now combines a long term share price gain with a deepening loss in the latest half year. The real tension is whether that mix still adds up to a fair valuation today.

Preferred Price-to-Sales of 4.6x: Is it justified?

Valuation views on Sunshine Lake Pharma are split. On one hand, the stock trades at a P/S of 4.6x, while our DCF estimate of future cash flows sits at HK$6.92 per share against a last close of HK$36.96.

The P/S ratio compares the company’s market value with its annual revenue, which can be useful when a business is loss making and earnings based ratios such as P/E cannot be applied. For a pharmaceutical group like Sunshine Lake Pharma, investors often lean on P/S to weigh current commercialised products and any revenue already flowing through the income statement.

Against this backdrop, the current 4.6x P/S sits below the peer average of 6.4x mentioned in the checks, which suggests the market is applying a lower revenue multiple than the broader peer set. At the same time, the same 4.6x level is described as expensive compared with the Hong Kong Pharmaceuticals industry average of 2x, which implies the valuation is richer than the industry as a whole and may be sensitive to any disappointment in future revenue delivery.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-sales of 4.6x (ABOUT RIGHT)

Still, the deepening CNY 603.72 million loss and a P/S above the wider Hong Kong pharmaceuticals industry could challenge confidence in the Sunshine Lake Pharma story.

Find out about the key risks to this Sunshine Lake Pharma narrative.

Another View on Sunshine Lake Pharma’s Value

The P/S comparison presents Sunshine Lake Pharma as cheaper than close peers but richer than the wider Hong Kong pharmaceuticals group. The SWS DCF model points the other way. It values the shares at HK$6.92, well below the HK$36.96 price. This highlights a very different risk profile for anyone buying today.

For readers who want to unpack the assumptions behind that gap, including growth, margins, and discount rates, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sunshine Lake Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 183 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

Conflicted about Sunshine Lake Pharma after these numbers and valuation checks? Act quickly, review the underlying data, then weigh it against the 2 important warning signs.

Looking for more investment ideas beyond Sunshine Lake Pharma?

If Sunshine Lake Pharma leaves you on the fence, do not stop there. Use the Simply Wall Street Screener to line up fresh ideas that match your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com